NCT02121353View on ClinicalTrials.gov

Safety Study of PF582 Versus Lucentis in Patients With Age Related Macular Degeneration

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

January 31, 2016

Study Completion Date

January 31, 2016

Conditions
Age Related Macular Degeneration (AMD)
Interventions
DRUG

Lucentis

Single-use 2 mL vial designed to deliver 0.05 mL of 10 mg/mL ranibizumab solution. Excipients: Alpha, alpha-trehalose dihydrate; histidine hydrochloride, monohydrate; histidine; polysorbate 20; water for injections Route of Administration: Intra-vitreal

DRUG

PF582

Single-use 2 mL vial designed to deliver 0.05 mL of 10 mg/mL ranibizumab solution. Excipients: Alpha, alpha-trehalose dihydrate; histidine hydrochloride, monohydrate; histidine; polysorbate 20; water for injections Route of Administration: Intra-vitreal

Trial Locations (2)

1050

Eye Institute, Remuera

Auckland Eye 8 St Marks Road Remuera Auckland 1050, Auckland

Sponsors

Lead Sponsor

Pfenex, Inc
All Listed Sponsors
lead

Pfenex, Inc

INDUSTRY